Attached files
| file | filename |
|---|---|
| EX-10.1 - EMPLOYMENT OFFER - ENTEST GROUP, INC. | entb20141106form8kex10_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2014
ENTEST BIOMEDICAL, INC.
(Exact Name of Company as Specified in Charter)
| Nevada | 333-154989 | 26-3431263 |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| 4700 Spring Street, Suite 304 |
| La Mesa California, 91942 |
| (Address of Principal Executive Offices, Zip Code) |
| 619-702-1404 |
| (Company’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02 Unregistered Sales of Equity Securities
On August 7, 2014 Entest BioMedical, Inc. ( the Company”) the Company issued 195,000,000 shares of the Company’s Common Stock ( “Shares”) to a creditor in satisfaction of $19,500 of principal indebtedness.
The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On August 11, 2014 the Company issued 12,500,000 shares of the Company’s Common Stock (“Shares”) as compensation to an employee.
The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.
On October 22, 2014 the Company issued 200,000,000 shares of the Company’s Common Stock ( “Shares”) to a creditor in satisfaction of $20,000 of principal indebtedness.
The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
Item 9.01 Exhibits.
Exhibit 10.1 Employment Offer Christine Ichim
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENTEST BIOMEDICAL, INC. | |
| Dated: November 7, 2014 | By: /s/ David Koos |
| David Koos | |
| Chief Executive Officer |